Azitra is trading at $0.85, with a -5.95% change in after-hours trading; no confirmed company-specific announcement explains the decline.
- Available coverage reported no news stories. Azitraβs October 26 release described positive ex vivo ATR-COSF results and anticipated initial human-study data by year-end, but does not establish the cause of this decline.
- Shares had already closed down 19.23% on October 28, following a 26.80% decline on October 27, amid sharp recent volatility.